Somewhat Positive Media Coverage Somewhat Unlikely to Impact Collegium Pharmaceutical (COLL) Share Price
News stories about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Collegium Pharmaceutical earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 44.1776977271566 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Analysts said to Buy stocks: Collegium Pharmaceutical, Inc. (COLL) ,Intellia Therapeutics Inc. (NTLA) – Street Observer (press release) (streetobserver.com)
- Collegium Pharmaceutical, Inc. (COLL) is at $10.59 per share and … – Stocks Gallery (stocksgallery.com)
- Zacks: Brokerages Anticipate Collegium Pharmaceutical, Inc. (COLL) Will Post Quarterly Sales of $5.00 Million (americanbankingnews.com)
- Healthcare Stock in Buy Zone: Collegium Pharmaceutical, Inc. (COLL) – Street Observer (press release) (streetobserver.com)
- Musculoskeletal Pains Market to Remain Consistent During 2017 to 2025 (medgadget.com)
A number of equities analysts have issued reports on the stock. Piper Jaffray Companies restated a “buy” rating and issued a $14.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. BidaskClub cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. HC Wainwright assumed coverage on shares of Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, Janney Montgomery Scott restated a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $19.50.
Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 0.48% during trading on Friday, hitting $10.49. 396,344 shares of the company traded hands. Collegium Pharmaceutical has a 52 week low of $9.68 and a 52 week high of $20.55. The company has a 50 day moving average price of $10.41 and a 200 day moving average price of $10.41. The company’s market capitalization is $310.15 million.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.09. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. On average, analysts expect that Collegium Pharmaceutical will post ($3.00) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Collegium Pharmaceutical (COLL) Share Price” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/30/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-collegium-pharmaceutical-coll-share-price.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.